Specific Detection of Antibodies to Emerging and Established Arboviruses Including Zika Virus
Specific Detection of Antibodies to Emerging and Established Arboviruses Including Zika Virus
批准号:
9347926
负责人:
DAVID CAMERINI
金额:
$22.5万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-02-06 至 2019-01-31
关键词:
AdultAlgorithmsAmericasAntibodiesArbovirusesAreaBiological AssayBurkholderia pseudomalleiChikungunya virusClinicalCountryCross ReactionsCulicidaeDengue VirusDetectionDevelopmentDiagnosticDiseaseEmergency SituationEpidemicEpitopesFloridaFutureGenomeGeographic stateGoalsGuillain-Barré SyndromeHawaiiHealthIncidenceIndigenousIndividualInfectionInternationalMelioidosisMethodsMexicoMicrocephalyNeurologicNeutralization TestsPathogenicityPatternPhaseProtein FragmentProtein MicrochipsProteinsProteomeProteomicsPublic HealthPuerto RicoReportingSalivaSerotypingSerumSpecificityTechnologyTestingUniversitiesVaccinesValidationViral ProteinsVirusVirus DiseasesWashingtonWest Nile viral infectionWest Nile virusWorkWorld Health OrganizationYellow fever virusZika Virusbasecombatcross reactivityin uteroinnovationmembernovel strategiespoint of carepublic health emergencyresponsesample collectionseropositivespecific biomarkerstherapeutic developmenttherapeutic vaccinetooltransmission process
中文摘要
摘要:
--
寨卡病毒(ZIKV)的感染目前仍是西半球西半球的主要疫情。世卫组织宣布,这是一种新的疫情。
《国际关注的公共卫生与紧急情况报告》自2016年2月1日起生效,这要归功于国际公共卫生与紧急事务协会的支持。
感染以小头畸形和其他神经系统异常为特征的婴儿在宫内和产后感染。
格林-巴利综合征出现在感染的成年人中。据估计,中国已有约400万人感染ZIKV。
2016年上半年,南美洲有超过20亿人生活在有利于减少蚊媒传播的地区。
寨卡病毒在全球范围内传播。到目前为止,中国还没有报告过本土寨卡病毒感染的病例。
西半球西北部的国家包括美国的自然保护国、波多黎各、墨西哥和佛罗里达州北部。
目前迫切需要一种准确的检测方法和一种实用的检测ZIKV病毒感染的方法,以及预防的方法。
新型治疗性药物和疫苗的开发有助于更好地抗击这种与艾滋病相关的疾病。
然而,由于抗ZIKV病毒抗体与其他虫媒病毒的交叉反应性差,感染过程受到了阻碍。
在两个相同的领域提供服务,包括欧洲DENV和中国CHIKV,反之亦然。具体地说,就是中和--
基于血清诊断试验(特别是斑块减少和中和试验,即PRNT)不能干净地检测。
区分这组虫媒病毒的不同成员之间的血清阳性反应,可能是因为
抗体针对的是中和表位,往往不会产生交叉反应。在这一应用中,我们将提出。
一种全新的、创新的、全面的测试方法,用于帮助发现非交叉反应测试的目标。
针对新出现的病毒和已建立的虫媒病毒的抗体,他们建议从ZIKV病毒开始,由于病毒的存在。
由这种病毒引发的国际公共卫生和紧急事件。
英文摘要
Abstract
Zika virus (ZIKV) infection is currently an epidemic in the western hemisphere. It is a WHO-declared
“Public Health Emergency of International Concern” since February 2016 due to the association of ZIKV
infection with microcephaly and other neurologic abnormalities in babies infected in utero and with
Guillain-Barre syndrome in infected adults. An estimated four million ZIKV infections have occurred in
the Americas in 2016 and over two billion people live in areas conducive to mosquito-borne
transmission of ZIKV worldwide. To date, autochthonous ZIKV infection has been reported in over 40
countries in the western hemisphere including the US protectorate, Puerto Rico, and state of Florida.
There is a clear need for accurate and practical methods of detecting ZIKV infection as well as for the
development of therapeutic agents and vaccines to combat the associated disease. Detection of ZIKV
infection is hampered, however, by the cross-reactivity of anti-ZIKV antibodies with other arboviruses
present in the same areas including DENV and CHIKV and visa-versa. Specifically, neutralization-
based serodiagnostic tests (notably plaque-reduction neutralization tests, PRNT) cannot cleanly
distinguish between seropositivity to different members of this set of arboviruses, perhaps because
antibodies directed at neutralizing epitopes tend to be cross-reactive. In this application we propose
an innovative and comprehensive method for discovering targets of non-cross-reactive
antibodies to emerging and established arboviruses and propose to begin with ZIKV due to the
international public health emergency created by this virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus
-
批准号:10259177
-
项目类别:
-
资助金额:$24.3万
-
财政年份:2021
-
负责人:DAVID CAMERINI
-
依托单位:
Discovery of Yellow Fever Virus-Specific Epitopes for Development of an Accurate Serodiagnostic Assay
-
批准号:9467246
-
项目类别:
-
资助金额:$29.96万
-
财政年份:2018
-
负责人:DAVID CAMERINI
-
依托单位:
Point of Care Detection of Oral Pathogens
-
批准号:8973923
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2015
-
负责人:DAVID CAMERINI
-
依托单位:
Development of a Pan-HIV Proteomic Chip
-
批准号:8659860
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:DAVID CAMERINI
-
依托单位:
HIV Pathogenesis and Immunity in Viremic Non-Progressors
-
批准号:8069963
-
项目类别:
-
资助金额:$18.97万
-
财政年份:2010
-
负责人:DAVID CAMERINI
-
依托单位:
HIV Pathogenesis and Immunity in Viremic Non-Progressors
-
批准号:7931065
-
项目类别:
-
资助金额:$22.98万
-
财政年份:2010
-
负责人:DAVID CAMERINI
-
依托单位:
Defensin mediated inhibition of HIV-1 replication
-
批准号:6954219
-
项目类别:
-
资助金额:$22.88万
-
财政年份:2004
-
负责人:DAVID CAMERINI
-
依托单位:
Defensin mediated inhibition of HIV-1 replication
-
批准号:6845911
-
项目类别:
-
资助金额:$22.76万
-
财政年份:2004
-
负责人:DAVID CAMERINI
-
依托单位:
HIV-1 Clones with Attenuated Cytopathic Effects
-
批准号:6744170
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2003
-
负责人:DAVID CAMERINI
-
依托单位:
HIV-1 Clones with Attenuated Cytopathic Effects
-
批准号:6655454
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2003
-
负责人:DAVID CAMERINI
-
依托单位:
PATHOGENESIS OF R5 HIV-1 ISOLATES
-
批准号:6374535
-
项目类别:
-
资助金额:$25.67万
-
财政年份:2000
-
负责人:DAVID CAMERINI
-
依托单位:
PATHOGENESIS OF R5 HIV-1 ISOLATES
-
批准号:6608017
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2000
-
负责人:DAVID CAMERINI
-
依托单位:
PATHOGENESIS OF R5 HIV-1 ISOLATES
-
批准号:6740219
-
项目类别:
-
资助金额:$31.41万
-
财政年份:2000
-
负责人:DAVID CAMERINI
-
依托单位:
PATHOGENESIS OF R5 HIV-1 ISOLATES
-
批准号:6511307
-
项目类别:
-
资助金额:$28.47万
-
财政年份:2000
-
负责人:DAVID CAMERINI
-
依托单位:
PATHOGENESIS OF R5 HIV-1 ISOLATES
-
批准号:6213536
-
项目类别:
-
资助金额:$30.66万
-
财政年份:2000
-
负责人:DAVID CAMERINI
-
依托单位:
PATHOGENESIS OF R5 HIV-1 ISOLATES
-
批准号:6554505
-
项目类别:
-
资助金额:$2.99万
-
财政年份:2000
-
负责人:DAVID CAMERINI
-
依托单位:
TESTING ANTIHIV-1 GENE THERAPY IN SCID-HU MICE
-
批准号:2429507
-
项目类别:
-
资助金额:$11.33万
-
财政年份:1996
-
负责人:DAVID CAMERINI
-
依托单位:
TESTING ANTIHIV-1 GENE THERAPY IN SCID-HU MICE
-
批准号:6169936
-
项目类别:
-
资助金额:$7.55万
-
财政年份:1996
-
负责人:DAVID CAMERINI
-
依托单位:
TESTING ANTIHIV-1 GENE THERAPY IN SCID-HU MICE
-
批准号:2076892
-
项目类别:
-
资助金额:$11.33万
-
财政年份:1996
-
负责人:DAVID CAMERINI
-
依托单位:
TESTING ANTIHIV-1 GENE THERAPY IN SCID-HU MICE
-
批准号:2672777
-
项目类别:
-
资助金额:$11.33万
-
财政年份:1996
-
负责人:DAVID CAMERINI
-
依托单位:
海外基金